Neurocrine Biosciencesvs.United Therapeutics
NBIX vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
United Therapeutics is about 1.6× larger than Neurocrine Biosciences by market cap; United Therapeutics trades at the lower P/E (17.4 vs 20.5); year to date, United Therapeutics leads (+9.3% vs −0.4%).
Side by side
| NBIX | UTHR | |
|---|---|---|
| Market cap | $14.4B | $22.9B |
| Price | $142.44 | $549.16 |
| Today | +0.8% | +3.1% |
| Return YTD | −0.4% | +9.3% |
| Return 1Y | +1.6% | +18.7% |
| Since June 26, 2026 | −15.5% | +1.2% |
| P/E | 20.5 | 17.4 |
| P/S | 4.3 | 7.2 |
| P/B | 3.9 | 3.6 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More NBIX & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.